Recombinant Human Fibrinogen Beta Chain (FGB) Protein (His)

Name: Recombinant Human Fibrinogen Beta Chain (FGB) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03953P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of this product could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) FGB.

Collections: High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Fibrinogen Beta Chain (FGB) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P02675
Target Symbol	FGB
Synonyms	Beta fibrinogen; Epididymis Secretory Sperm Binding Protein Li 78p; FGB; FIBB_HUMAN; Fibrinogen beta chain; Fibrinogen; B Beta Polypeptide; HEL-S-78p
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	GHRPLDKKREEAPSLRPAPPPISGGGYRARPAKAAATQKKVERKAPDAGGCLHADPDLGVLCPTGCQLQEALLQQERPIRNSVDELNNNVEAVSQTSSSSFQYMYLLKDLWQKRQKQVKDNENVVNEYSSELEKHQLYIDETVNSNIPTNLRVLRSILENLRSKIQKLESDVSAQMEYCRTPCTVSCNIPVVSGKECEEIIRKGGETSEMYLIQPDSSVKPYRVYCDMNTENGGWTVIQNRQDGSVDFGRKWDPYKQGFGNVATNTDGKNYCGLPGEYWLGNDKISQLTRMGPTELLIEMEDWKGDKVKAHYGGFTVQNEANKYQISVNKYRGTAGNALMDGASQLMGENRTMTIHNGMFFSTYDRDNDGWLTSDPRKQCSKEDGGGWWYNRCHAANPNGRYYWGGQYTWDMAKHGTDDGVVWMNWKGSWYSMRKMSMKIRPFFPQQ
Expression Range	45-491aa
Protein Length	partial
Mol. Weight	54.8kDa
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.
Subcellular Location	Secreted.
Database References	HGNC: 3662 OMIM: 134830 KEGG: hsa:2244 STRING: 9606.ENSP00000306099 UniGene: PMID: 29134563 Compared with the patients with TT genotypes of fibrinogen beta, expressions of fibrinogen, IL-6 and CRP were significantly higher in the patients with the CC and CT genotypes. PMID: 29165755 Two novel fibrinogen Bbeta chain mutations in two Slovak families with hypofibrinogenemia/afibrinogenemia have been described. PMID: 29286337 FGB c.490G>A indicated the activation of a cryptic splice site causing the insertion of 99 bp in intron 3. This splicing abnormality led to the production of a Bbeta-chain possessing 33 aberrant amino acids, including two Cys residues in the coiled-coil domain. Therefore, a splicing abnormality may cause impaired fibrinogen assembly and secretion. PMID: 29156616 FGB mutations leading to congenital hypofibrinogenaemia PMID: 28306188 Fibrinogen Bbeta448Lys variant is associated with thrombotic fibrin clots in type 2 diabetic patients independently of traditional risk factors. PMID: 27929198 There was underexpression of the majority of genes after sunitinib treatment. The lower expression levels of IGFBP1, CCL20, CXCL6 and FGB were confirmed by qRT-PCR in all cases. The downregulation of gene expression leads us to search for methylation as a mechanism of action of the tyrosine kinase inhibitors PMID: 27834463 elevated levels of plasma homocysteine /homocysteine thiolactone contribute to AD pathology via the Abeta-fibrin(ogen) interaction PMID: 27090576 procoagulant changes in fibrin metastructure appear to result from excessive carbonylation of fibrinogen, which may compensate for a decrease in fibrinogen level in patients with cirrhosis PMID: 26833718 Prognostic impact of plasma fibrinogen levels in patients with esophageal squamous cell carcinoma PMID: 28064398 a tight cluster of alternating multiple splicing regulatory elements and U1 snRNA binding sites controls cryptic splice donor usage throughout the human fibrinogen Bbeta-chain gene (FGB) exon 7 PMID: 28039323 The plasma fibrinogen level was found to be a possible biomarker for clinical response to chemotherapy and postoperative metastasis or death in advanced breast cancer patients who received neoadjuvant chemotherapy PMID: 28621233 Data suggest that, in the binding of fibrin beta N-domains and the (1-8) peptide fragment of VLDLR (very low density lipoprotein receptor), the second and third Lys/Arg clusters in fibrin make major contributions to this interaction while the contribution of the first cluster is moderate. PMID: 28437098 The novel missense mutation in the FGB gene causes afibrinogenemia most probably by affecting the secretion of the fibrinogen beta-chain. PMID: 27824214 fibrinogen aggregation is accompanied by the formation of beta-sheet conformation, and induction of non-native helical segments in the protein inhibits aggregation PMID: 27150313 fibrinogen is an independent predictor of the angiographic presence of coronary artery disease in hypertensive patients. PMID: 27553289 novel mutation was identified in exon 2 of FGB caused by c.221G> T (dagger) substitution PMID: 27812779 Our results show that higher levels of circulating chemerin, CRP, fibrinogen, and ESR are associated with an increased risk of developing colorectal cancer PMID: 26628300 We assessed the diagnostic accuracy of a newly developed laboratory score-based on CA125, platelet count (PLT), C-reactive protein (CRP), and fibrinogen levels-in the preoperative diagnosis of adnexal mass PMID: 26499778 the mechanical properties of individual fibrin fibers formed from blood plasma, were examined. PMID: 27028649 Here we report a new B[beta] gene mutation (Fibrinogen St Kilda) identified in two Caucasian sisters with reduced fibrinogen level (1.2-1.6 g/L) during investigation for recurrent early miscarriages. PMID: 26308135 desAB fibrin binds to prothrombin through the Bbeta26-42 amino acid residues and the formation of such a complex causes a non-enzymatic activation of prothrombin PMID: 26317125 Strong positive association has been found between betatrophin, plasma fibrinogen (FBG), and insulin resistance in non-diabetic subjects. Correlations with FBG and insulin resistance were diminished in type 2 diabetes subjects. PMID: 26077345 These experiments demonstrate, for the FGB-p.Asp185Asn mutation, a pathogenic mechanism not common for fibrinogen deficiencies, i.e. the hyperglycosylation of the Bbeta chain due to the introduction of a novel N-glycosylation motif. PMID: 26006300 High plasma fibrinogen levels and platelet count are associated with esophageal squamous cell carcinoma. PMID: 25896470 Results suggest that FGB -148 C/T and -854 G/A polymorphisms probably contribute to susceptibility of ischemic stroke in Chinese population. PMID: 25890854 The results of the meta-analysis indicate that the -455 G>A polymorphism in the beta-fibrinogen gene is a susceptibility marker of ischemic cerebral infarction in the Chinese population. PMID: 25398500 In the present study, we found that the -148C>T polymorphism in the FGB gene was significantly associated with ischemic stroke in a Chinese population [meta-analysis] PMID: 25867317 This prospective study in 110 patients undergoing major cardiovascular surgery at risk of post-cardiopulmonary bypass bleeding compares fibrinogen level. PMID: 26011420 the NGR motif in fibrinogen is the site that is primarily responsible for the interaction with resting alphaIIbbeta3 and is responsible for triggering platelet activation PMID: 25413489 Elevated fibrinogen levels are associated with negative tumor response to therapy in rectal cancer. PMID: 25384698 Four novel FGB mutations were identified in two afibrinogenemic (one new-born and one 30 years old male) and hypofibrinogenemic (a 49 years old female) patient, with heterogeneous thrombotic and bleeding phenotype PMID: 24560896 plasma fibrinogen increase during ischemic stroke has a role in worse outcome PMID: 24531853 meta-analysis suggests that the FGB-455G/A polymorphism contributes to susceptibility to ischemic stroke and coronary heart disease PMID: 24448059 results of our meta-analysis suggested that the-148C>T polymorphism in the FGB gene is a susceptibility marker of ischemic stroke PMID: 24720800 The A + genotype of the FGB -455 G/A polymorphism associated with poor survival among 55-71 years old Caucasian women in the Finnish stroke cohort. PMID: 24957141 results indicate that FGbeta-455G/A polymorphism may be a susceptible predictor of ischemic stroke [meta-analysis] PMID: 24366241 Elevated fibrinogen is associated with idiopathic sudden hearing loss. PMID: 24466284 High fibrinogen levels are associated with gynecologic cancer. PMID: 25204086 Both fibrinogen polymorphisms are capable to modify the atherosclerotic process via their effects on the coagulation cascade. PMID: 23931975 The beta-fibrinogen -455G/A gene polymorphism is not a risk factor for ischaemic stroke in a Polish population. PMID: 23650004 A meta-analysis of a Chinese population found that the FgB -455G/A and the -148C/T gene polymorphism was implied to be associated with coronary artery disease susceptibility. PMID: 23129316 Both isoforms of the beta-chain of FIB discovered by 2D-gel electrophoresis are decreased in the Parkinson's disease group cerebrospinal fluid, compared to normal controls. PMID: 22889670 Lys, as an inhibitor of protein glycation, improved fibrinogen's structure and function, both in vitro and in vivo. PMID: 22575419 Fibrinogen polymorphisms contributes to the association between common variants in the fibrinogen gene and the risk of developing sporadic cerebral hemorrhage. PMID: 22386478 study found that -C148T FGB polymorphism was an independent predictor of pre- and early postoperative C-reactive protein levels in coronary artery bypass graft patients PMID: 21499712 genetic polymorphism is associated with plasma fibrinogen levels and haematological traits in whites, blacks and mexican americans PMID: 22273812 Levels of fibrinogen and thromboelastometry fibrin polymerisation following treatment with desmopressin (DDAVP). PMID: 22293628 The BF -455G/A polymorphisms was found to be positively. PMID: 21241403 Fibrinogen has chaperone activity which is compromised upon glycation by methylglyoxal. PMID: 22053176

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.